These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38011461)

  • 1. Evaluation of rivaroxaban versus warfarin for the treatment of cerebral vein thrombosis: A case-control blinded study.
    Khorvash F; Farajpour-Khanaposhtani MJ; Hemasian H; Saadatnia SM
    Curr J Neurol; 2021 Jul; 20(3):125-130. PubMed ID: 38011461
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of rivaroxaban in cerebral venous thrombosis: insights from a prospective cohort study.
    Pan L; Wang M; Zhou D; Ding Y; Ji X; Meng R
    J Thromb Thrombolysis; 2022 Apr; 53(3):594-600. PubMed ID: 34731403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban for the treatment of cerebral venous thrombosis.
    Esmaeili S; Abolmaali M; Aarabi S; Motamed MR; Chaibakhsh S; Joghataei MT; Mojtahed M; Mirzaasgari Z
    BMC Neurol; 2021 Feb; 21(1):73. PubMed ID: 33588777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of oral rivaroxaban in cerebral venous thrombosis.
    Maqsood M; Imran Hasan Khan M; Yameen M; Aziz Ahmed K; Hussain N; Hussain S
    J Drug Assess; 2020 Dec; 10(1):1-6. PubMed ID: 33391859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Single-Center Retrospective Evaluation of the Use of Oral Factor Xa Inhibitors in Patients With Cerebral Venous Thrombosis.
    Powell M; Tremolet de Villers K; Schwarz K; Case D; Trujillo T
    Ann Pharmacother; 2021 Mar; 55(3):286-293. PubMed ID: 32844675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Vitamin K Antagonist Oral Anticoagulants for the Treatment of Cerebral Venous Sinus Thrombosis: a Retrospective, Matched Cohort Analysis.
    Giles JA; Balasetti VKS; Zazulia AR
    Neurocrit Care; 2021 Dec; 35(3):783-788. PubMed ID: 34046861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban for the treatment of cerebral venous thrombosis: a single-center experience.
    Bajko Z; Maier S; Motataianu A; Filep RC; Stoian A; Andone S; Balasa R
    Acta Neurol Belg; 2022 Feb; 122(1):105-111. PubMed ID: 33733345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT).
    Connor P; Sánchez van Kammen M; Lensing AWA; Chalmers E; Kállay K; Hege K; Simioni P; Biss T; Bajolle F; Bonnet D; Grunt S; Kumar R; Lvova O; Bhat R; Van Damme A; Palumbo J; Santamaria A; Saracco P; Payne J; Baird S; Godder K; Labarque V; Male C; Martinelli I; Morales Soto M; Motwani J; Shah S; Hooimeijer HL; Prins MH; Kubitza D; Smith WT; Berkowitz SD; Pap AF; Majumder M; Monagle P; Coutinho JM
    Blood Adv; 2020 Dec; 4(24):6250-6258. PubMed ID: 33351120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.
    Bruins Slot KM; Berge E
    Cochrane Database Syst Rev; 2013 Aug; (8):CD008980. PubMed ID: 23925867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial.
    Ferro JM; Coutinho JM; Dentali F; Kobayashi A; Alasheev A; Canhão P; Karpov D; Nagel S; Posthuma L; Roriz JM; Caria J; Frässdorf M; Huisman H; Reilly P; Diener HC;
    JAMA Neurol; 2019 Dec; 76(12):1457-1465. PubMed ID: 31479105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Observational Study to Evaluate the Effectiveness of Rivaroxaban in the Management of Cerebral Venous Sinus Thrombosis.
    Fatima M; Asghar MS; Abbas S; Iltaf S; Ali A
    Cureus; 2021 Mar; 13(3):e13663. PubMed ID: 33824814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful use of rivaroxaban in postoperative deep vein thrombosis of the lower limb following instability with warfarin: a case report.
    Schiavoni M; Coluccia A
    J Med Case Rep; 2016 Oct; 10(1):276. PubMed ID: 27716428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
    Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Warfarin and Rivaroxaban in the Treatment of Cerebral Venous Thrombosis.
    Fayyaz M; Abbas F; Kashif T
    Cureus; 2019 May; 11(5):e4589. PubMed ID: 31309014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study.
    Yaghi S; Shu L; Bakradze E; Salehi Omran S; Giles JA; Amar JY; Henninger N; Elnazeir M; Liberman AL; Moncrieffe K; Lu J; Sharma R; Cheng Y; Zubair AS; Simpkins AN; Li GT; Kung JC; Perez D; Heldner M; Scutelnic A; Seiffge D; Siepen B; Rothstein A; Khazaal O; Do D; Kasab SA; Rahman LA; Mistry EA; Kerrigan D; Lafever H; Nguyen TN; Klein P; Aparicio H; Frontera J; Kuohn L; Agarwal S; Stretz C; Kala N; El Jamal S; Chang A; Cutting S; Xiao H; de Havenon A; Muddasani V; Wu T; Wilson D; Nouh A; Asad SD; Qureshi A; Moore J; Khatri P; Aziz Y; Casteigne B; Khan M; Cheng Y; Mac Grory B; Weiss M; Ryan D; Vedovati MC; Paciaroni M; Siegler JE; Kamen S; Yu S; Leon Guerrero CR; Atallah E; De Marchis GM; Brehm A; Dittrich T; Psychogios M; Alvarado-Dyer R; Kass-Hout T; Prabhakaran S; Honda T; Liebeskind DS; Furie K
    Stroke; 2022 Mar; 53(3):728-738. PubMed ID: 35143325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety Assessment of Rivaroxaban for the Treatment of Cerebral Venous Sinus Thrombosis in a Chinese Population.
    Jiang YY; Chen LJ; Wu XJ; Zhou GQ; Mo DC; Li XL; Liu LY; Li JL; Luo M
    Clin Appl Thromb Hemost; 2022; 28():10760296221144038. PubMed ID: 36503260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).
    Sherwood MW; Douketis JD; Patel MR; Piccini JP; Hellkamp AS; Lokhnygina Y; Spyropoulos AC; Hankey GJ; Singer DE; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Becker RC;
    Circulation; 2014 May; 129(18):1850-9. PubMed ID: 24552831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
    Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
    Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban and atrial fibrillation: continue to use warfarin or in some cases, dabigatran.
    Prescrire Int; 2012 Nov; 21(132):257-60. PubMed ID: 23210252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.